Review
Open access
Oct 2026
The impact of beta-blocker treatment on all-cause mortality and rehospitalization in general population with heart failure with preserved ejection fraction and comorbidity-specific subgroups
The benefits of beta-blocker treatment in heart failure have been firmly established in individuals with reduced ejection fraction (EF), yet the debate persists regarding the potential effects of this therapy among patients with EF > 40%, with particularly conflicting results in those diagnosed with heart failure...
R. Szczerba, J. Sokołowski, W. Żelazna et al.
· European Heart Journal · 0 citations